Put company on watchlist
MorphoSys AG
ISIN: DE0006632003
WKN: 663200
About
Company Snapshot
New: Activate notification
Be informed about new publications
New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

MorphoSys AG · ISIN: DE0006632003 · Newswire (Company)
Country: Deutschland · Primary market: Germany · EQS NID: 1809537
08 January 2024 08:00AM

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 


EQS-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 

08.01.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Media Release

Planegg/Munich, Germany, January 8, 2024

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company’s Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions. 

A live webcast of the presentation can be accessed on the Investors section of MorphoSys’ website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company’s website following the presentation.

About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.

For more information, please contact:

Media Contacts:
Thomas Biegi
Senior Vice President, Corporate Affairs
Tel: +49 (0)151 / 74612318
thomas.biegi@morphosys.com
Investor Contact:
Dr. Julia Neugebauer
Vice President, Global Investor Relations
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Eamonn Nolan
Director, Corporate Communications & Investor Relations
Tel: +1 617-548-9271
eamonn.nolan@morphosys.com
 


08.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1809537

 
End of News EQS News Service

1809537  08.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1809537&application_name=news&site_id=boersengefluester_html
smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 24.11.2024, Calendar Week 47, 329th day of the year, 37 days remaining until EoY.